Professional Documents
Culture Documents
INDUSTRY
INTERNSHIP REPORT
Submitted by
ARULPRASAAD A M
(611219423001)
MASTER OF ENGINEERING
IN INDUSTRIAL SAFETY
ENGINEERING
DEPARTMENT OF MECHANICAL
AUGUST2020
1
ACKNOWLEDGEMENT
With deep sense of gratitude, I extend my earnest and sincere thanks to my class
advisor Mr.G.THANGARAJ M.E., Assistant professor, Department of Mechanical
Engineering for the kind guidance and encouragement.
ABSTRACT 6
1 INTRODUCTION 7
1.2.6 16
1.3 17
4
2.1 HAZARD AND CONTROL MEASURES 18
8.1 CONCLUSION 39
ABSTRACT
Biocon was founded in 1978 with ₹10,000 (US$140) as the initial capital. Now the total
assets of this company is ₹14,443.80 crore (US$2.0 billion)
· 1979 - Becomes the first Indian company to manufacture and export enzymes to USA and
Europe.
· 1989 - Unilever acquires Biocon Biochemicals Ltd. in Ireland and merges it with its
subsidiary, Quest International; Biocon receives US funding for proprietary technologies.
· 1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon
becomes an independent entity.
· 2001 - Becomes the first Indian company to be approved by USFDA for the manufacture
of lovastatin; Pla Fractor is granted a US 2001 and worldwide patent.
· 2003 - Biocon becomes the first company worldwide to develop human insulin on
a Pichia expression system.
· 2006 - BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for
head-and-neck cancer is launched and Dr. APJ Abdul Kalam inaugurates India's Largest
Biotech-Hub "Biocon Park".
· 2008 - Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.
· 2009 - Syngene -Bristol Myers Squibb research facility is established in Bengaluru.
· 2009 - Mylan announces strategic collaboration with Biocon to Enter the Global Generic
Biologics Market.
· 2011 - Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery
device.
· 2012 - Abbott announces collaboration with Syngene to Open First Nutrition R&D Center
in India.
· 2014 - Biocon launches world's first biosimilar drug CANMAb to treat breast cancer.
· 2016 - Becomes the first Indian company to launch a biosimilar Insulin Glargine pen in
Japan.
· 2017 - Biocon's Insugen is the first locally manufactured biosimilar product to be approved
for sale by the Malaysian drug regulator.
· 2018 - Biocon, Mylan get European Commission approval to market biosimilar insulin
glargine.
Fig. No. 1.2 Company view
S.No Details Description
5 Category : Orange
RAW MATERIAL
API SYNTHESIS
CHEMICAL /
BIOLOGICAL PROCESS
PRELIMINARY
PURIFICATION
CENTRIFUGATION
FILTRATION
CRYSTALLISATION
DRYING
TAP MILL
MICRONISATION
BLENDING
PACKING
DISPATCH
Active Pharmaceutical Ingredient (API) is defined by U.S. Food & Drug
Administration as: any substance or mixture of substances intended to be used as
the active ingredient in the manufacture of a drug (medicinal) product. Such
substances are intended to furnish pharmacological activity or other direct effect
in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect
the structure or function of the body. API may exist in the form of liquids,
powders, crystals and extracts that obtained by chemical synthesis, plant
extraction, or biotechnology and is not taken by patients directly. Only when API
is processed into a pharmaceutical preparation, can the product be used for
clinical use. The synthesis of APIs is usually a complicated and multi-step
process involving numerous chemical transformations and operations on a range
of raw materials with different physical and chemical properties. Specialized
expertise is needed to achieve the synthesis of these molecules.
1.3 EHS (ENVIRONMENT HEALTH AND SAFETY)
Our EHS Management System and the Occupational Health and Safety
Management Systems are established in compliance with ISO 14001:2015 and
OHSAS 18001:2007, respectively.
The comprehensive EHS Management System encompasses all operations in
manufacturing, research & development, supply chain network, as well as,
administration.
In our constant endeavour to raise the bar, we are transitioning to the new
ISO 45001:2018 standard, the first global standard and a single benchmark for
management of Occupational Health and Safety. Continuous self-evaluation,
correction and improvement of operations and processes based on findings of
annual internal and external audits continue to lead us to the next orbit in EHS.
Periodic Mutual Aid meetings were organised with representatives from nearby
industrial units for enabling collaboration and swift response during any
emergency.
EHS TRAINING AND EMPLOYEE ENGAGEMENT:
We organized close to 22,000 man hours of training for our employees
across 346 sessions covering chemical safety, lab safety, fire safety, emergency
preparedness, first aid and advanced process safety.
As a part of our commitment to enhance employee awareness on EHS-
related matters, several awareness campaigns were held around World
Environment Day, National Safety Week, Fire Services Week, World Water
Day, and World Ozone Day.
CHAPTER 2
5. Emergency
Handling checklist
and procedure
6. Pressure alarm High and
Pressure alarm low for
Storage Tanks
7. Level indicators with
monitoring from control for
storage tanks
29-10-2020 THURSDAY
1. Risk assessment
2. Emergency response plan.
2.
CHAPTER 8
8.1 CONCLUSION:
Our humble thanks and regards to our Biocon Limited., Bangalore
for giving this great opportunity, it’s very useful for us to learn technical
knowledge and skills on safety in the period of internship. This Internship helps us
to develop our career in future and guide us to implement safety at workplace.